Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)
NCT04317092Phase 2Unknown
- Sponsor
- National Cancer Institute
- Start
- Mar 2020
- Primary completion
- Dec 2023
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in COVID-19 pneumonia, sponsored by National Cancer Institute. Status: unknown.
02
Drugs
tocilizumab
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04317092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04317092.